US Edition
AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook - AstraZeneca (NASDAQ:AZN)
UNITED STATES, JUL 29 – AstraZeneca’s oncology sales rose 18% to $6.31 billion in Q2 2025, driven by US demand and regulatory progress, supporting its $50 billion US investment plan.
9 Articles
9 Articles
AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook - AstraZeneca (NASDAQ:AZN)
AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, driven by double-digit growth in oncology and biopharmaceuticals. The company's adjusted EPADS reached $1.08, missing the consensus of $1.10. The adjusted EPS was $2.17 (1 ADR = 2 Common Shares). Also Read: Trump Tariffs Force AstraZeneca To Bring Subs…
Evening Standard
The IndependentCancer drug demand drives higher sales for AstraZeneca
Revenues from oncology products made up 43% of the company’s total sales.
economiadigital.es
El PluralAstraZeneca presented its results for the first half of the year, in which it highlighted an 11% increase in total revenues, which reached 28,045 million dollars. It also closed the second quarter with revenues of 2.457 million dollars, also with an increase of 11% compared to the same period of the previous year. The company’s solid performance was driven by a two-digit growth in the areas of Oncology and Biopharmaceuticals, with a positive evo…
English-Swedish pharmaceutical recipe increased from US$ 12,94 billion to US$ 14,46 billion in the period, and only in the US, it grew 13%, reaching a record of US$ 6,32 billion
Astrazeneca sees demand for cancer drugs soar as it mulls US listing
Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year, driven by double-digit growth in Oncology and BioPharmaceuticals, the pharmaceutical giant told markets this morning
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
